Legend Biotech Results Presentation Deck
7
Expanding Our Manufacturing Capabilities
Bringing cell therapies to market given unique challenges to improve overall supply
State-Of-The-Art CARVYKTI Manufacturing Facilities
ā
ā
Obelisc Facility in Ghent, Belgium received license from
the Federal Agency for Medicines and Health Products in
Belgium for clinical supply manufacturing
Awaiting Investigational Medicinal Product Dossier
approvals from local authorities
Anticipate manufacturing cilta-cel at Ghent for clinical
use by the end of the year
Janssen In-House Lentivirus Facilities
Janssen facility in Switzerland now producing
Lentivirus in-house
All commercial Lentivirus now produced in-house and
we are self-sufficient
Additional LV supply is expected to be available from
Janssen facilities in US and Netherlands in 2024 an
2025, respectively
This presentation is for investor relations purposes only - Not for product promotional purposes
Novartis as CMO for Clinical Supply
Signed CMO agreement with Novartis during
Q2 2023
On track to produce clinical materials in 1H
2024
LEGEND
BIOTECHView entire presentation